We are conscious of the responsibility we share for present and future generations and weigh all our actions in terms of their impact on the environment, society, patients and employees.
Code of Conduct
MorphoSys' Code of Conduct defines the ethical principles in how we conduct business and ourselves. It is the compass that guides us and our partners in the decisions we make each day, helping us build trust with people living with cancer and their families, healthcare professionals, shareholders and the public. All MorphoSys colleagues and leaders are responsible for living our Code of Conduct and holding each other accountable for the same. To access our Code of Conduct click here.
U.S. Compliance Program
MorphoSys’ Compliance Program is anchored by the company’s Credo and Code of Conduct, designed on several key regulations and guidance and comprised of multiple compliance streams that focus on anti-bribery, risk management and transparency and disclosure efforts. We recognize that an effective compliance program evolves to changing circumstances and therefore, we are committed to continuous improvement based on regular reviews, assessments and developments. To access more information on our Compliance Program click here.
Valuing diversity and ensuring equal opportunities are firmly anchored in our corporate culture.
At MorphoSys, we strongly believe that every single colleague needs to be heard and plays an important role in contributing to our success. We therefore are committed to policies that do not discriminate in recruitment, hiring, training, promotion or other employment practices for reasons of race, color, religion, gender, gender identity, national origin, age, sexual orientation, marital or protected veteran status, medical condition, pregnancy, disability or any other legally protected status. We aim for an open working environment where creativity and innovation can flourish.
MorphoSys’ CEO Dr. Jean-Paul Kress signed the “CEO Pledge for a More Equitable and Inclusive Life Sciences Industry” initiated by the Massachusetts Biotechnology Council to demonstrate the commitment of MorphoSys and the whole biotechnology industry to diversity and inclusion.
Based on the most recent recommendations of the German Corporate Governance Code, the Supervisory Board of MorphoSys has updated its objectives for its composition and has established a diversity concept pursuant to the German Commercial Code (HGB).
We are conscious of the responsibility we share for present and future generations and see sustainable action as a prerequisite for long-term business success. To ensure this, we see it as our responsibility to incorporate Environmental, Social and Governance criteria into our daily business and base our business model on sustainable growth that is aligned with the interests of all of our stakeholders. By doing so, we are focused on creating long-term value and weigh our actions in terms of their impact on the environment, society, patients and employees.